louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00489879: Management of Patients With Type 2 Diabetes and Hypertension Using Mobile Health Care System
Official title: Efficacy of Mobile Health Care System in Patients With Type 2 Diabets and Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Hypertension
Obesity
Keywords: Mobile Health Units
Chronic Disease
Lead sponsor: Korea University
Sponsor class: OTHER
First posted: 2007-06-21
Enrollment: 140
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to determine whether cellular phone based health care system is effective in the treatment of diabetes and hypertension.

Detailed description: Diabetes care is facilitated by a patient's being engaged in a self-management program with the advice and counsel of physicians, but many diabetic patients can not receive the continous monitoing and advice from his physician in their every day life. It is very difficult to keep up life style modification in their real life.

Few studies have examined the effects of cellular phone based intervention that provide an interactive component daily. Our goal is to test the hypothesis that diabetes and hypertension management using cellular phone based health care system would result in significant improvement of blood glucose and blood pressure level.

Eligibility criteria: Inclusion Criteria:

* type II diabetes using only oral hypoglycemic agents
* 7% \< HbA1c \< 10%
* systolic blood pressure \> 130 or diastolic blood pressure \> 80
* BMI \> 23
* 20 \< age \< 75

Exclusion Criteria:

* type I diabetes or type II diabtes using insulin treatment
* liver, renal or heart disease
* recent change (within 1 month) in the type or dosage of anti-diabetic agent, anti-hypertensive medication

Primary outcomes:
measure: HbA1c, fasting blood glucose level, Weight change, Blood pressure level in the morning, lipid profiles
timeFrame: baseline, 3months later
Secondary outcomes:
measure: exercise time during one week, self reported change in dietary habit, fat consumption ratio
timeFrame: baseline, 3months later
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Internal Medicine, Korea University College of Medicine
state: VD
Study officials:
affiliation: Department of Internal Medicine, Korea University College of Medicine
name: Kyung M Choi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kwon HS, Cho JH, Kim HS, Song BR, Ko SH, Lee JM, Kim SR, Chang SA, Kim HS, Cha BY, Lee KW, Son HY, Lee JH, Lee WC, Yoon KH. Establishment of blood glucose monitoring system using the internet. Diabetes Care. 2004 Feb;27(2):478-83. doi: 10.2337/diacare.27.2.478.
Clinical trial NCT00179179: The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis
Official title: The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: End Stage Renal Disease
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To test the hypothesis that an exercise session combined with adequate nutritional supplementation improves skeletal muscle protein accretion during a hemodialysis session.


Eligibility criteria: Inclusion Criteria:

* On hemodialysis for more than 3 months, on a thrice weekly hemodialysis program.
* Adequately dialyzed (Kt/V \> 1.2).
* Age 18-75

Exclusion Criteria:

* Pregnant women.
* Patients unable to perform exercise
* Severe unstable underlying disease besides commonly associated with ESRD. Cardiac patients that are stable will be included.
* Patients hospitalized within the last month prior to the study.
* Patients with malfunctioning arterial-venous access (recirculation and/or blood flow \< 750 ml/min)
* Patients receiving steroids and/or other immunosuppressive agents.

Primary outcomes:
measure: improvement in net protein muscle balance
timeFrame: 10 hours
Secondary outcomes:
measure: improvement in net whole body protein balance
timeFrame: 10 hours
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Alp Ikizler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01096979: An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity
Official title: A Double-Masked, Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Subcutaneous Abdominal Adiposity
Keywords: Subcutaneous Adipose Tissue Reduction
Lead sponsor: Neothetics, Inc
Sponsor class: INDUSTRY
First posted: 2010-03-31
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-masked evaluation of the safety and efficacy of LIPO-102 for the reduction of subcutaneous abdominal adiposity.


Eligibility criteria: Inclusion Criteria:

* Male or non pregnant female
* Good general health
* Sufficient abdominal fat for injections
* Signed informed consent
* BMI greater than or equal to 18 and less than 28 kg/m2
* History of stable weight in past 3 months

Exclusion Criteria:

* Known hypersensitivity to study drugs
* Treatment with an investigational agent within 30 days of first dose

Primary outcomes:
measure: Safety
timeFrame: 8 weeks
measure: Reduction in abdominal adiposity
timeFrame: 8 weeks
measure: Waist circumference
timeFrame: 8 weeks
Secondary outcomes:
measure: Photographic assessments
timeFrame: 8 weeks
measure: Skin-fold caliper measurements
timeFrame: 8 weeks
measure: Patient and clinician Global Impression of severity survey
timeFrame: 8 weeks
measure: Patient and clinician global impression of change questions
timeFrame: 8 weeks
measure: Abdominal appearance questionnaire
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Anaheim
country: United States
state: California
city: San Diego
country: United States
state: California
Study officials:
References:
Clinical trial NCT02863679: Postoperative Analgesic Efficacy of Tetracaine Hydrochloride Gel
Official title: Topical Anesthesia of Tetracaine Hydrochloride Jelly on Cervix After Hysteroscopic Uterine Stent Insertion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hysteroscopy
Keywords: tetracaine hydrochloride gel
analgesia
intrauterine balloon
hysteroscope operation
Lead sponsor: Wenzhou Medical University
Sponsor class: OTHER
First posted: 2016-08-11
Enrollment: 84
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was taken out to assess the postoperative analgesic efficacy of tetracaine hydrochloride gel in patients with intrauterine adhesion treating with intrauterine balloon.Participates were assigned into two groups by randomly-tetracaine hydrochloride gel group and control group.

Detailed description: Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics. Patients in getracaine hydrochloride gel group were covered with a gauze of tetracaine hydrochloride gel on the external cervical orifice after insert an utrauterine balloon in the uterine cavity. While patients in the control group were covered with a blank gauze after hysteroscopic adhesiolysis. Compare the postoperative analgesic scor and patients' analgesic satisfaction of the two groups and asess the analgesic efficacy of tetracaine hydrochloride gel.

Eligibility criteria: Inclusion Criteria:

* no previous history of hysteroscopic adhesiolysis or surgery on the cervix
* inserted intrauterine balloon in the uterine cavity after hysteroscopic adhesiolysis
* no other diseases

Exclusion Criteria:

* Allergy to local anesthetics
* Patients with chronic pain
* Patients with abnormal blood coagulation function
* Patients with mental illness that can not cooperate
* Patients with previous hysteroscopic adhesiolysis or cervical surgery

Primary outcomes:
measure: Numerical Rating Scale (NRS) score
timeFrame: 7 days
Secondary outcomes:
measure: patients received balloon volume reduction
timeFrame: 1 day
Other outcomes:
Locations:
city: Wenzhou
country: China
facility: the 1st Affiliated Hospital of Wenzhou Medical College
state: Zhejiang
Study officials:
affiliation: The 1st Affiliated Hospital of Wenzhou Medical University
name: Feng Lin, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Weaver CS, Rusyniak DE, Brizendine EJ, Abel S, Somerville GG, Howard JD, Root T. A prospective, randomized, double-blind comparison of buffered versus plain tetracaine in reducing the pain of topical ophthalmic anesthesia. Ann Emerg Med. 2003 Jun;41(6):827-31. doi: 10.1067/mem.2003.192.
citation: Amiel H, Koch PS. Tetracaine hydrochloride 0.5% versus lidocaine 2% jelly as a topical anesthetic agent in cataract surgery: comparative clinical trial. J Cataract Refract Surg. 2007 Jan;33(1):98-100. doi: 10.1016/j.jcrs.2006.09.013.
Clinical trial NCT04749979: Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin
Official title: Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin in IVF Cycles
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
Collaborators: name: Cairo University
First posted: 2021-02-11
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Estradiol valerate in the form of cycloprogenova™ (white tablet only) was started on day 2 or 3 of cycle with oral dose 4 mg divided on 2 doses in addition to Aspocid 75 mg once daily with folic acid 500 mcg once daily.

Detailed description: U/S was done on day 9 or 10 of cycle to assess endometrial thickness, then every other day until endometrial thickness of 8 mm or more is reached and when endometrial thickness reaches 8 mm or more FET was planned. Progesterone in the form of prontogest™ 400 mg vaginal suppository twice dTwo to Four Day 5 Embryos was transferred

Eligibility criteria: Inclusion Criteria:

* PCOS patients according to Rotterdam criteria
* Female age between 20 and 40 years.
* Primary or secondary infertility.
* Body mass index (BMI) between 18 and 40 kg/m2.

Exclusion Criteria:

* Ovarian endometriosis.

  * Ovarian cysts before induction.
  * Known uncontrolled endocrinal abnormalities (like hypo or hyperthyroidism)

Primary outcomes:
measure: the number of good quality embryos
timeFrame: within 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Aljazeera( Al Gazeera) hospital
Study officials:
affiliation: Algezeera hospitaland National Research Centre ,Egypt
name: Mahmoud Alalfy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03486379: Folfiri as Third Line of Treatment
Official title: FOLFIRI as a Second-line Therapy in Patients With Docetaxel-pretreated Gastric Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastric Cancer
Ramucirumab
Third Line
Lead sponsor: IRCCS Cancer Referral Center of Basilicata
Sponsor class: OTHER
First posted: 2018-04-03
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with metastatic gastric cancer progressed after two lines of treatment including ramucirumab-based therapy.

Brief summary: The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.


Eligibility criteria: Inclusion Criteria:

* Patients with histologically confirmed, ramucirumab pretreated metastatic gastric cancer who received
* Eastern Cooperative Oncology Group performance status ≤2 (ECOG PS)
* aged \> 18 years
* neutrophil count ≥1500/μl
* platelet count ≥100 000/μl),
* renal (serum creatinine ≤1.5 mg/dl)
* liver (serum bilirubin ≤2 mg/dL) functions
* normal cardiac function,
* absence of second primary tumor other than non-melanoma skin cancer
* no concurrent uncontrolled medical illness.

Exclusion Criteria:

* Eastern Cooperative Oncology Group performance status \>2 (ECOG PS)
* No prior treatment with ramucirumab
* operable metastatic disease were excluded from the study
* severe cardiac dysfunction, congestive heart failure or a recent myocardial infarction
* uncontrolled sites of infection.

Primary outcomes:
measure: response rate (confirmed complete and partial response).
timeFrame: From date of enrollment to best radiological evaluation, up to 12 months
Secondary outcomes:
measure: Progression free survival
timeFrame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
measure: Overall survival
timeFrame: From date of enrollment until the date of death from any cause, whichever came first, assessed up to 12 months
measure: Toxicity
timeFrame: From date to start therapy up to 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06352879: Prevalence, Types and Risk Factors of Urinary Incontinence Among Women in Baghdad, Iraq.
Official title: Prevalence, Types and Risk Factors of Urinary Incontinence Among Women Attending Primary Healthcare Centers in Baghdad, Iraq.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Urinary Incontinence
Urge Incontinence
Stress Incontinence
Keywords: Urinary Incontinence
Urge incontinence
Stress incontinence
Mixed incontinence
Lead sponsor: Al-Kindy College of Medicine
Sponsor class: OTHER
First posted: 2024-04-08
Enrollment: 384
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Adult women attending primary healthcare centers in Baghdad, Iraq

Brief summary: The goal of this observational study is to observe and describe the prevalence, types, and risk factors of urinary incontinence (UI) in adult women attending primary healthcare centers in Baghdad, Iraq. The main questions it aims to answer are:

* What is the prevalence of incontinence among the targeted group?
* What are the types of incontinence and what is the frequency of each type among the targeted group?
* What is the effect of several risk factors on the occurrence and severity of urinary incontinence (including age, job, sexual activity, chronic constipation, chronic cough, parity, largest birth weight, and body mass index)? Participants will be asked to fill out a questionnaire consisting of the Arabic International Consultation On Incontinence Questionnaire-Urinary Incontinence Short Form (Arabic ICIQ-UI SF) in addition to questions about the aforementioned risk factors.


Eligibility criteria: Inclusion Criteria:

* women
* Attending the primary healthcare centers in Baghdad, Iraq
* older than 18 years

Exclusion Criteria:

* Patients who refuse to participate in the study.

Primary outcomes:
measure: Arabic International Consultation On Incontinence Questionnaire-Urinary Incontinence Short Form (Arabic ICIQ-UI SF)
timeFrame: 3 months
Secondary outcomes:
measure: Risk factors for urinary incontinence
timeFrame: 3 months
Other outcomes:
Locations:
city: Baghdad
country: Iraq
facility: Baghdad Al- Karkh Health Directorate
city: Baghdad
country: Iraq
facility: Baghdad Al-Russafa Health Directorate
Study officials:
affiliation: University of Baghdad / Alkindy collage of medicine
name: Harth Mohamed Kamber, FICMS (Uro.)
role: STUDY_CHAIR
References:
Clinical trial NCT06224179: Role of Ultrasound Guided Transversus Abdominis Plane Block in Pain Control After Hepatectomy
Official title: Ultrasound Guided Oblique Subcostal Transversus Abdominis Plane Block(TAP) Versus Both Subcostal and Posterior TAP Block as Postoperative Analgesia in Hepatectomy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Analgesia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-01-25
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Inadequately managed acute pain following abdominal surgery originates from somatic pain signals in the abdominal wall and is linked to various unfavorable postoperative outcomes. These consequences encompass patient distress, respiratory complications, delirium, myocardial ischemia, extended hospital stays, an elevated risk of chronic pain, heightened analgesic consumption, delayed bowel function, and an increased need for rescue analgesics.

This study aims to assess the postoperative analgesic efficacy of ultrasound-guided Transversus Abdominis Plane (TAP) block using oblique subcostal and posterior approaches in hepatectomy.

Detailed description: Pain control is vital to achieve enhanced recovery after abdominal surgeries . TAP block had been demonstrated to improve pain related outcomes after abdominal surgeries.

Postoperative pain management for patients undergoing hepatic resection is a challenge due to the risk of perioperative liver dysfunction.TAP block is a promising regional analgesic technique. This study aimed to evaluate the effect of US-guided subcostal approach versus combination of both subcostal and posterior approaches of TAP block

The patients will be randomly divided into two groups :

group A will recieve oblique subcostal TAP block and group B will recieve both subcostal and posterior TAP block .

Eligibility criteria: Inclusion Criteria:

* ASA I and II patients. aged 18 to 50 years. 70 to 80 kg.

Exclusion Criteria:

* patients under 18 years of age.

  * History of Allergic reactions to study drugs.
  * Opioid or analgesic abuse, and chronic treatment with opioids, or non-steroidal anti-inflammatory drugs.
  * History of bleeding tendency or coagulopathy .

Primary outcomes:
measure: postoperative analgesia (VAS) during the 1st 24 hours in ICU
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03850379: Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Official title: Ciprofloxacin Versus Levofloxacin and Rate of Breakthrough Infections in Hematopoietic Stem Cell Transplant Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prophylaxis
Stem Cell Transplant Complications
Lead sponsor: Henry Ford Health System
Sponsor class: OTHER
First posted: 2019-02-21
Enrollment: 308
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers. In some small retrospective studies ciprofloxacin prophylaxis was associated with a higher rate of breakthrough gram positive bloodstream infections. However, the optimum oral agent for antibacterial prophylaxis in transplant recipients remains uncertain.


Eligibility criteria: Inclusion Criteria:

* Patients 18-75 years of age with a diagnosis of a hematological malignancy. Meet the stem cell transplant program criteria to undergo autologous or allogeneic hematopoietic stem cell transplantation.

Exclusion Criteria:

* Prolonged QT
* Allergies to ciprofloxacin or levofloxacin

Primary outcomes:
measure: incidence of bloodstream bacterial infections
timeFrame: 60 days post stem cell transplant
Secondary outcomes:
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Henry Ford
state: Michigan
Study officials:
References:
citation: Farhan S, Mazur I, Hartzell S, Xie P, Neme K, German A, Mikulandric N, Patel K, Wu M, Kortam N, Yaseen A, Sweidan A, Latack K, Emole J, Peres E, Abidi MH, Ramesh M. Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial. Int J Infect Dis. 2024 Oct;147:107172. doi: 10.1016/j.ijid.2024.107172. Epub 2024 Jul 15.
Clinical trial NCT01438879: Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR)
Official title: Molecular Methods in the Etiological Diagnostics of Acute Central Nervous System Infections: Lymphocytic Herpesviruses and PCR
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Central Nervous System Infection
Keywords: CSF
PCR
lymphocytic herpesvirus
CNS
Lead sponsor: PaijatHame Central Hospital
Sponsor class: OTHER
Collaborators: name: University of Turku
First posted: 2011-09-22
Enrollment: 60
Sex: ALL
Minimum age (years): 16
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents of the district of Paijat-Hame (200 000 inhabitants).

Brief summary: Enterovirus and herpes simplex viruses 1 and 2 are the main causative agents of central nervous system infections.

Instead, the role of lymphocytic herpesviruses in the etiology of central nervous system (CNS) infections is not clear, even if there is the positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR)-result for the virus.

The aim of this study is to evaluate the presence of DNA from lymphocytic herpesviruses in the CSF obtained from the immunocompetent patients with CSF pleocytosis and from the patients with normal CSF leukocyte count.


Eligibility criteria: Inclusion Criteria:

* Immunocompetent patients with clinical symptoms and signs of central nervous system infections and CSF pleocytosis (pleocytosis group)
* Immunocompetent patients without suspicion of CNS infection and no CSF pleocytosis (non-pleocytosis group)

Exclusion Criteria:

* Suspicion of CNS-infection, eg. encephalitis, but no CSF leukocytosis (pleocytosis group)
* Patients without symptoms of CNS infection, but who has CSF pleocytosis of unknown origin (non-pleocytosis group)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Lahti
country: Finland
facility: PaijatHame Central Hospital
Study officials:
affiliation: PaijatHame Central Hospital
name: Laura MA Kupila
role: PRINCIPAL_INVESTIGATOR
References: